An Introduction to Multiple Sclerosis
Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the CNS and one of the most common causes of neurological disability in adults. It is characterized by a relapsing-remitting clinical course, which progresses to a more chronic progressive phase, although a minority have a progressive course from onset. Numerous disease-modifying therapies (DMTs) have emerged, including oral (fingolimod, dimethyl fumarate, teriflunomide, cladribine, siponimod, ozanimod), injectable (glatiramer acetate, pegylated interferon beta-1a) and intravenous (alemtuzumab, ocrelizumab) options. Challenges include switching therapies in patients who become refractory to initial treatment. MS is also the fastest growing indication for autologous haematopoietic stem cell transplantation in Europe, with a growing body of evidence supporting its use in highly active relapsing-remitting MS that does not respond to DMTs.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Multiple Sclerosis Content
What is the new normal for the treatment of multiple sclerosis in the age of COVID-19?
A panel of internationally renowned experts provide an update on MS treatment and assessment practices in the context of COVID-19. For subtitles in French, German, Italian, Russian and Spanish, please click [CC] on the video player below.
Systemic Sclerosis Revealed by a Primary Progressive Multiple Sclerosis-like Condition: A Case Report
touchREVIEWS in Neurology. 2021;17(1):Online ahead of journal publication
Neurologic manifestations in systemic sclerosis are rare, occurring in 0.8–5.6% of patients. Peripheral neuropathy is one of the most common neurologic abnormalities, with central nervous system involvement reported less frequently.1 Central nervous system (CNS) manifestation has been described in a few cases,1–3 and has been explained by a compressive mechanism or through metabolic disorders due to gastrointestinal […]
Patrick Vermersch, EAN 2021: Future Treatment Paradigm of Multiple Sclerosis
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the future developments expected in the treatment paradigm of multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Disease-modifying therapies in multiple sclerosis: Current perspectives on the latest data
Watch international experts discuss the latest data for highly effective disease-modifying therapies and changes in treatment approach for patients with multiple sclerosis.
- Describe the latest data informing the use of disease-modifying therapies in the treatment of multiple sclerosis
- Evaluate the potential benefit of early treatment with highly effective disease-modifying therapies for patients with multiple sclerosis
- Explain how patient-centric decision making can improve outcomes
Anthony Traboulsee, AAN 2021: The use of Tolebrutinib in Relapsing Multiple Sclerosis Treatment
TouchNEUROLOGY had the pleasure of meeting with Anthony (Tony) Traboulsee (University of British Columbia, Vancouver, Canada) to discuss the Phase 2b study investigating tolebrutinib in patients with highly active relapsing multiple sclerosis. The abstract entitled: ‘Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study’ was […]
Jiwon Oh, AAN 2021: Fenebrutinib in Multiple Sclerosis
Dr Jiwon Oh (University of Toronto, Canada) caught up with touchNEUROLOGY to discuss investigating fenebrutinib as a potential Multiple Sclerosis therapy. The abstract entitled: ‘The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)’ was presented at the American Academy of Neurology Virtual Annual Meeting […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!